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Abstract
The bone morphogenetic protein (BMP) type II receptor (BMPR2) has a long cytoplasmic tail domain whose function
is incompletely elucidated. Mutations in the tail domain of BMPR2 are found in familial cases of pulmonary arterial
hypertension. To investigate the role of the tail domain of BMPR2 in BMP signaling, we generated a mouse carrying
a Bmpr2 allele encoding a non-sense mediated decay-resistant mutant receptor lacking the tail domain of Bmpr2. We
found that homozygous mutant mice died during gastrulation, whereas heterozygous mice grew normally without
developing pulmonary arterial hypertension. Using pulmonary artery smooth muscle cells (PaSMC) from
heterozygous mice, we determined that the mutant receptor was expressed and retained its ability to transduce BMP
signaling. Heterozygous PaSMCs exhibited a BMP7‑specific gain of function, which was transduced via the mutant
receptor. Using siRNA knockdown and cells from conditional knockout mice to selectively deplete BMP receptors, we
observed that the tail domain of Bmpr2 inhibits Alk2‑mediated BMP7 signaling. These findings suggest that the tail
domain of Bmpr2 is essential for normal embryogenesis and inhibits Alk2‑mediated BMP7 signaling in PaSMCs.
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Introduction
Bone morphogenetic proteins (BMPs) were initially identified
as signaling factors involved in the formation of bone and
cartilage. BMPs are now known to participate in a broad
spectrum of biological activities during embryogenesis and
organogenesis, as well as in the homeostasis of mature organs
[1,2]. BMPs are members of the transforming growth factor
beta family. BMPs bind to heterotetrameric receptor complexes
formed by BMP type 2 and BMP type 1 serine–threonine
kinases. Upon assembly of the BMP receptor complex by a
BMP ligand, the constitutively active type 2 receptor
phosphorylates the type 1 receptor, which in turn activates
cytoplasmic BMP-responsive Smad signaling molecules—
Smads 1, 5, and 8. Phosphorylated BMP-responsive Smads
interact with Smad4 and translocate into the nucleus, where
they modulate the transcription of BMP-responsive genes, such
as Id1 and Smad6 [2-4].
BMP receptors include four type 1 (Alk1, Alk2, Alk3 and
Alk6) and three type 2 kinases (Bmpr2, Acvr2a and Acvr2b) [2].
The expression of these receptors differs depending on the cell
type or tissue. For example, mouse pulmonary artery smooth
muscle cells (PaSMCs) express Bmpr2 and Acvr2a with lower
amounts of Acvr2b; Alk2 and Alk3 are the predominant BMP
type 1 receptors expressed in PaSMCs [5]. All BMP receptors
have a similar structure including an extracellular ligand-
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binding domain, a transmembrane domain, and a cytoplasmic
serine–threonine kinase domain. Unlike other BMP receptors,
the predominantly expressed form of Bmpr2 (Bmpr2‑WT)
contains a long cytoplasmic tail domain (Bmpr2‑TD) encoded
by Bmpr2 exons 12 and 13 [6,7]. In a small fraction of Bmpr2
transcripts, exon 12 is alternatively spliced, resulting in a short-
form variant of the receptor [7]. Although the Bmpr2‑TD has
been reported to interact with several proteins that can
modulate BMP signaling [8,9], the functional role of the
Bmpr2‑TD remains to be fully defined.
BMPR2 is implicated in the development of pulmonary
arterial hypertension (PAH) [10,11]. PAH is a disease of the
pulmonary circulation characterized by neointimal formation,
obstruction of vessels, plexiform lesions, and pruning of the
small pulmonary arteries [12]. Heterozygous BMPR2 mutations
have been reported in approximately 75% of patients with
hereditary PAH and in 25% of idiopathic cases [13]. Seventy
percent of BMPR2 mutations introduce a premature termination
codon [14]. BMPR2 transcripts containing premature
termination codons are subject to nonsense-mediated decay
(NMD), an RNA surveillance mechanism that degrades
aberrant mRNAs [15,16]. BMPR2 transcripts that undergo
NMD lead to functional haploinsufficiency. However, some
types of mutant transcripts can escape NMD, and the
translated mutant receptor may exhibit a more deleterious
phenotype by acting, for example, in a dominant-negative
manner. It has been reported that PAH has an earlier onset
and a worse prognosis in patients that carry NMD-resistant
BMPR2 mutations than in patients who carry NMD-sensitive
BMPR2 mutations [17].
In previous studies, we examined the impact of Bmpr2
haploinsufficiency on BMP signaling in PaSMCs isolated from
genetically modified mice. We observed that PaSMCs isolated
from heterozygous mice carrying a Bmpr2 mutant allele lacking
exons 4 and 5 (Bmpr2+/-) were less responsive to BMP4 and
BMP7 than were PaSMCs isolated from WT mice [5,18]. We
also investigated the impact of complete loss of Bmpr2 using
PaSMCs from mice harboring mutant Bmpr2 alleles in which
exon 4 and 5 were flanked with loxP sequences (Bmpr2flox/flox)
[5]. When both Bmpr2 alleles were disrupted (Bmpr2del/del) in
PaSMCs, BMP4 signaling was diminished, whereas BMP7
signaling was unexpectedly increased. We found that Acvr2a,
but not Acvr2b, compensated for the absence of Bmpr2.
To investigate the role of the tail domain of Bmpr2 and model
the impact of an NMD-resistant Bmpr2 mutation, we generated
mice that carry a mutant Bmpr2 allele (Bmpr2Δtd), which
encodes a receptor lacking the tail domain of Bmpr2
(Bmpr2‑ΔTD). We isolated PaSMCs from mice carrying the
Bmpr2Δtd allele to characterize the role of Bmpr2-TD in BMP
signaling.
Results
Generation and phenotype of mutant mice harboring
the Bmpr2Δtd allele
The mutant Bmpr2Δtd allele was generated by inserting a
cassette encoding the enhanced green fluorescent protein
(Egfp) and a stop codon in frame after exon 11. The strategy
for generating mice carrying the mutant Bmpr2Δtd allele is
described in Methods and Figure S1. We observed that
Bmpr2Δtd/Δtd mice died early in embryogenesis (embryonic day
(E) 7.5 to 8.5), revealing a previously unknown role for the
Bmpr2‑TD in embryogenesis. In contrast, Bmpr2Δtd/+ mice grow
normally and have a lifespan similar to that of their WT
littermates. Right ventricular systolic pressure and mean
arterial pressure did not differ between Bmpr2Δtd/+ and WT mice
at 6 to 8 months of age (Figure S2). These findings suggest
that Bmpr2Δtd/+ mice do not spontaneously develop PAH.
Expression of Bmpr2‑ΔTD in PaSMCs
To begin to understand the impact of the Bmpr2Δtd allele on
BMP signaling, we sought to determine whether the mutant
Bmpr2 gene is expressed. Bmpr2+ and Bmpr2Δtd mRNA and
protein levels were measured in PaSMCs using quantitative
real-time PCR (qPCR) and immunoblot techniques,
respectively. Total Bmpr2 mRNA levels did not differ between
WT and Bmpr2Δtd/+ PaSMCs, when determined using
oligonucleotides spanning the Bmpr2 exon 6–7 junction (Figure
1A). Bmpr2+ mRNA levels in Bmpr2Δtd/+ PaSMCs were half of
those observed in WT cells when measured using
oligonucleotides spanning the exon 12–13 junction.
Immunoblot analysis showed that levels of Bmpr2‑WT were
less in Bmpr2Δtd/+ PaSMCs than in WT PaSMCs. The protein
expressed by the mutant allele, Bmpr2‑ΔTD, in Bmpr2Δtd/+ cells
was smaller (~100 kDa) than Bmpr2‑WT (Figure 1B). These
results show that the Bmpr2Δtd allele is transcribed, Bmpr2Δtd
transcripts are resistant to NMD, and Bmpr2‑ΔTD protein is
expressed in PaSMCs.
To determine whether Bmpr2‑ΔTD can localize to the cell
membrane, PaSMCs were transfected with a plasmid directing
the expression of Bmpr2Δtd, following by immunostaining with
an antibody directed against GFP. Confocal microscopy
revealed that the mutant receptor localized to the cell
membrane (Figure 1C). This finding suggests that the
Bmpr2‑TD is not required for intracellular trafficking of
Bmpr2‑WT to the cell membrane.
Bmpr2Δtd/+ PaSMCs exhibit a BMP ligand-specific gain
of function
The observation that Bmpr2‑ΔTD localizes to the cell
membrane suggested that the mutant receptor could
participate in BMP signaling. To investigate the impact of the
Bmpr2‑TD on BMP signaling, we compared PaSMCs from WT
and Bmpr2Δtd/+ mice. Incubation with BMP4 induced the
phosphorylation of Smad1/5/8 and expression of the Id1 gene
similarly in WT and Bmpr2Δtd/+ PaSMCs (Figure 2A and B). In
both WT and Bmpr2Δtd/+ PaSMC, BMP4 induction of Id1 gene
expression peaked at 4 hours (Figure 2A) and persisted for up
to 24 hours (Figure S3). In contrast, incubation with BMP7 for
1.5 and 4 hours led to a greater induction of Smad1/5/8
phosphorylation and Id1 and Smad6 gene expression in
Bmpr2Δtd/+ PaSMCs than in WT cells (Figure 2B and C). After 8
hours of exposure to BMP7, levels of Id1 mRNA returned to
baseline (Figure 2B). These findings suggest that loss of one
copy of the Bmpr2‑TD leads to a BMP ligand-specific gain of
function.
Bmpr2 Tail Domain Regulates BMP7 Signaling
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Bmpr2‑ΔTD contributes to the increased
responsiveness of Bmpr2Δtd/+ PaSMCs to BMP7
To investigate whether the enhanced responsiveness of
Bmpr2Δtd/+ PaSMCs to BMP7 depends on the presence of
Bmpr2‑ΔTD, Bmpr2Δtd/+ PaSMCs were treated with small
interfering RNAs (siRNAs) to silence Bmpr2+ mRNA (targeting
Bmpr2 exon 12; siBmpr2‑ex12) or Bmpr2Δtd mRNA (targeting
Egfp; siEgfp). The ability of BMP7 to induce Id1 and Smad6
gene expression was retained in Bmpr2Δtd/+ PaSMCs treated
with siBmpr2‑ex12, but decreased in cells treated siEgfp
(Figure 3A). These data suggest that the enhanced BMP7
signaling seen in Bmpr2Δtd/+ PaSMCs requires Bmpr2‑ΔTD.
To confirm that the increased BMP7 signaling seen in
Bmpr2Δtd/+ cells does not require expression of the wild-type
allele, we infected PaSMCs from Bmpr2Δtd/flox mice with an
adenovirus specifying Cre recombinase (Ad-Cre) to delete the
Bmpr2flox allele (Bmpr2Δtd/del PaSMCs). Bmpr2Δtd/flox cells infected
with an adenovirus specifying red fluorescent protein (Ad-RFP)
were used as control. Bmpr2Δtd/del PaSMCs did not express
detectable Bmpr2‑WT protein (Figure S4). Incubation with
BMP4 led to a similar induction of Smad1/5/8 phosphorylation
(Figure 3B) and Id1 and Smad6 gene expression (Figure 3C) in
Bmpr2Δtd/flox and Bmpr2Δtd/del PaSMCs. In contrast, incubation
with BMP7 led to a greater increase in the phosphorylation of
Smad1/5/8 and in Id1 and Smad6 gene expression in
Bmpr2Δtd/del than in Bmpr2Δtd/flox PaSMCs. These results provide
additional support for the concept that the presence of
Bmpr2‑WT is not required for Bmpr2Δtd/flox PaSMCs to signal in
response to BMP7. Moreover, the presence of the Bmpr2+
allele appears to inhibit signaling via Bmpr2‑ΔTD.
Since Acvr2a, but not Acvr2b, can compensate for the
absence of Bmpr2 in Bmpr2del/del PaSMCs [5], we considered
the possibility that Acvr2a was responsible for BMP signaling in
Bmpr2Δtd/+ or Bmpr2Δtd/del PaSMCs. Silencing Acvr2a mRNA
modestly increased the ability of BMP4 to induce Id1 gene
expression in Bmpr2Δtd/+ PaSMCs, as well as the ability of
BMP4 to induce Smad6 gene expression in Bmpr2Δtd/+ and
Bmpr2Δtd/del PaSMCs (Figure 4). These findings show that
Acvr2a is not required for BMP4 signaling in Bmpr2Δtd/+ or
Bmpr2Δtd/del PaSMCs. In contrast, silencing Acvr2a mRNA
modestly decreased the ability of BMP7 to induce Id1 and
Smad6 gene expressions in Bmpr2Δtd/del PaSMCs (Figure 4), as
well as decreasing the ability of BMP7 to induce Id1 gene
expression in Bmpr2Δtd/+ PaSMCs. These findings show that
Bmpr2‑ΔTD and, to a lesser extent, Acvr2a can transduce
BMP7 signaling in PaSMCs harboring the Bmpr2Δtd allele.
Alk2 is required for the response of Bmpr2Δtd/+ PaSMCs
to BMP7
Based on our previous findings in Bmpr2del/del PaSMCs [5]
and the high affinity of BMP7 for Alk2 [19,20], we hypothesized
that the response to BMP7 would be less in Bmpr2Δtd/+ cells
deficient in Alk2 than in Bmpr2Δtd/+ cells that express Alk2. To
test this hypothesis, we generated Bmpr2Δtd/+ mice carrying
Alk2, Alk3, or both alleles flanked by loxP sequences. PaSMCs
from these mice were infected with Ad-Cre to delete alleles
flanked by loxP sequences or Ad-RFP as a control. Incubation
with BMP4 induced Id1 and Smad6 gene expression similarly
in Bmpr2Δtd/+; Alk2flox/flox and Bmpr2Δtd/+; Alk2del/del PaSMCs
(Figure 5A). In contrast, incubation with BMP4 induced Id1 and
Smad6 gene expression less in Bmpr2Δtd/+; Alk3del/del than in
Figure 1.  Bmpr2 expression in PaSMCs obtained from WT or Bmpr2Δtd/+ mice.  (A) Levels of Bmpr2 mRNA were measured in
WT (Bmpr2+/+) or Bmpr2Δtd/+ PaSMCs by qPCR using hydrolysis probes for Bmpr2 exon junctions 6–7 and 12–13. Bmpr2 mRNA
levels were normalized to Gapdh and expressed as the fold-change relative to Bmpr2+/+ PaSMCs. *P < 0.01 compared to Bmpr2+/+
PaSMCs. (B) Immunoblots prepared from lysates of Bmpr2+/+ and Bmpr2Δtd/+ PaSMCs were incubated with an antibody directed
against the tail domain of Bmpr2 to detect Bmpr2‑WT or with an anti-GFP antibody to detect Bmpr2‑ΔTD. Immunoblots were
subsequently incubated with an antibody directed against Gapdh as a control for protein loading. (C) Confocal microscopy image of
a PaSMC transiently transfected with a plasmid directing expression of Bmpr2Δtd and reacted with an anti-GFP antibody showing
localization of Bmpr2‑ΔTD at the cell membrane.
doi: 10.1371/journal.pone.0076947.g001
Bmpr2 Tail Domain Regulates BMP7 Signaling
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Bmpr2Δtd/+; Alk3flox/flox PaSMCs (Figure 5B). The ability of BMP7
to induce Id1 and Smad6 gene expression was markedly less
in Bmpr2Δtd/+; Alk2del/del than in Bmpr2Δtd/+; Alk2flox/flox PaSMCs
and was similar in Bmpr2Δtd/+; Alk3flox/flox and Bmpr2Δtd/+; Alk3del/del
PaSMCs (Figure 5). These results suggest that the enhanced
responsiveness of Bmpr2Δtd/+ PaSMCs to BMP7 requires the
presence of Alk2. To corroborate these results, we examined
the contribution of Bmpr2‑ΔTD or Bmpr2‑WT to mediate BMP7
signaling in PaSMCs predominantly expressing Alk2 (i.e. in
Alk3‑deficient PaSMCs). Silencing of Bmpr2+ transcripts in
Bmpr2Δtd/+; Alk3del/del PaSMCs augmented the ability of BMP7 to
induce Id1 or Smad6 gene expression, whereas silencing of
Figure 2.  BMP7 signaling is enhanced in Bmpr2Δtd/+ PaSMCs.  (A) Immunoblots of lysates of WT (Bmpr2+/+) or Bmpr2Δtd/+
PaSMCs treated with BMP4 or BMP7 (10 ng/ml) for various times were reacted with antibodies directed against phosphorylated and
total Smad1/5/8. Quantification of the ratio of phosphorylated Smad1/5/8 to total Smad1/5/8 (analysis of 3 independent experiments)
demonstrated that BMP4 signaling is similar in Bmpr2+/+ or Bmpr2Δtd/+ PaSMCs, whereas BMP7 signaling is greater in Bmpr2Δtd/+
PaSMCs. *P<0.05 compared to Bmpr2+/+ PaSMC group treated with BMP7. Id1 (B) and Smad6 (C) mRNA levels were measured by
qPCR in Bmpr2+/+ or Bmpr2Δtd/+ PaSMCs treated with BMP4 or BMP7 (10 ng/ml) for various times. Id1 and Smad6 gene expression
was normalized to Gapdh and expressed as fold-change relative to control Bmpr2+/+ PaSMC group. *P < 0.01 compared to Bmpr2+/+
PaSMC group treated with BMP7.
doi: 10.1371/journal.pone.0076947.g002
Bmpr2 Tail Domain Regulates BMP7 Signaling
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Bmpr2Δtd transcripts reduced the responsiveness of Bmpr2Δtd/+;
Alk3del/del PaSMCs to BMP7 (Figure 6). These results support
the concept that BMP7 signaling is transduced by the mutant
receptor Bmpr2‑ΔTD and Alk2, and suggest that the tail
domain of Bmpr2 may inhibit BMP7 signaling via Alk2. Deletion
of both Alk2 and Alk3 abrogated BMP4 and BMP7 signaling in
Figure 3.  Bmpr2‑ΔTD contributes to BMP7 signaling in Bmpr2Δtd/+ PaSMCs.  (A) Bmpr2Δtd/+ PaSMCs were transfected with
negative control siRNA (siNC), siBmpr2‑ex12, or siEgfp (30 nM). After 48 h, the ability of BMP7 (10 ng/ml for 1.5 h) to induce Id1
and Smad6 mRNA expression was measured by qPCR, normalized to Gapdh and expressed as fold-change relative to Bmpr2Δtd/+
PaSMCs transfected with siNC. *P < 0.01 compared to siNC group treated with BMP7, † P<0.01 compared to siBmpr2‑ex12 group
treated with BMP7. Efficiency of silencing Bmpr2+ (siBmpr2‑ex12) and Bmpr2Δtd (siEgfp) transcripts was measured by qPCR. (B)
Bmpr2Δtd/flox and Bmpr2Δtd/del PaSMCs were treated with BMP4 or BMP7 (10 ng/ml) for 30 and 60 minutes, upon which the activation
of Smad1/5/8 was evaluated by immunoblotting. Quantification of the Smad1/5/8 activation is plotted as the ratio of pSmad1/5/8 to
total Smad1/5/8. (C) The ability of BMP4 or BMP7 to induce Id1 and Smad6 gene expression in Bmpr2Δtd/flox and Bmpr2Δtd/del
PaSMCs was measured by qPCR, normalized to Gapdh and expressed as fold-change relative to untreated Bmpr2Δtd/flox PaSMCs.
*P < 0.01 compared to Bmpr2Δtd/flox PaSMC group treated with BMP7.
doi: 10.1371/journal.pone.0076947.g003
Bmpr2 Tail Domain Regulates BMP7 Signaling
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Bmpr2Δtd/+ PaSMCs, as well as in Bmpr2+/+ PaSMCs (Figure
S5). These findings suggested that the very low levels of Alk6
detected in PaSMCs are insufficient to transduce BMP
signaling.
Discussion
In this study, we report the generation of a genetically
modified mouse that carries a Bmpr2 allele with an NMD-
resistant mutation in the sequences encoding the Bmpr2‑TD.
We found that Bmpr2Δtd/Δtd mice die early in embryogenesis
(E7.5‑8.5) and that Bmpr2Δtd/+ mice appear to grow normally.
RVSP is similar in Bmpr2Δtd/+ mice and their WT littermates at 6
to 8 months of age. We observed that the receptor encoded by
the mutant allele, Bmpr2‑ΔTD, is expressed and traffics to the
membrane of PaSMCs. In PaSMCs from Bmpr2Δtd/+ mice, we
found a BMP7‑specific gain of signaling with preserved BMP4
signaling. Knockdown of Bmpr2+ transcripts in Bmpr2Δtd/+
PaSMCs or deletion of the Bmpr2flox allele in conditional
Bmpr2Δtdlflox PaSMCs showed that Bmpr2‑WT is not required for
these cells to transduce signaling in response to BMP7.
However, knockdown of Bmpr2Δtd transcripts in Bmpr2Δtd/+
PaSMCs inhibited BMP7 signaling. Finally, we determined that
the increased responsiveness of Bmpr2Δtd/+ PaSMCs to BMP7
relies on the presence of Alk2, thus revealing that the tail
domain of Bmpr2 inhibits Alk2‑mediated signaling.
Figure 4.  BMP7 signaling in Bmpr2Δtd/+ and Bmpr2Δtd/del PaSMCs does not depend on the presence of Acvr2a.  (A) Bmpr2Δtd/+
PaSMCs were treated with a siRNA specific for Acvr2a transcripts. The ability of BMP4 or BMP7 (10 ng/ml for 1.5 h) to induce Id1
and Smad6 gene expression was measured by qPCR, normalized to Gapdh and expressed as fold-change relative to Bmpr2Δtd/+
PaSMCs treated with siNC. *P < 0.01 compared to siNC within BMP treatment. Silencing efficiency was quantified by measuring
Acvr2a mRNA levels. (B) Bmpr2Δtd/del PaSMCs were treated with siAcvr2a. The ability of BMP4 or BMP7 (10 ng/ml for 1.5 h) to
induce Id1 and Smad6 gene expression was measured by qPCR, normalized to Gapdh and expressed as fold-change relative to
Bmpr2Δtd/del PaSMCs treated with siNC. *P < 0.01 compared to siNC within BMP treatment. Acvr2a silencing efficiency was
measured by qPCR.
doi: 10.1371/journal.pone.0076947.g004
Bmpr2 Tail Domain Regulates BMP7 Signaling
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In the process of posttranscriptional regulation, the mRNA
surveillance mechanism of NMD plays a critical role degrading
aberrant transcripts prior to translation [16,17]. It was
conceivable that transcripts generated by the Bmpr2Δtd allele
would undergo NMD. We observed, however, that Bmpr2Δtd
mRNA represented half of the Bmpr2 transcripts expressed in
Bmpr2Δtd/+ PaSMCs. Likewise, Bmpr2‑ΔTD protein expression
was readily detected in lysates from PaSMCs expressing the
Bmpr2Δtd allele. These data show that transcripts from the
Bmpr2Δtd allele were resistant to NMD. Our mouse model
differs from other genetically modified mice carrying mutations
in the Bmpr2-TD. Mutant transcripts from heterozygous mice
carrying a BMPR2 R899X knockin allele were found to be
subject to NMD [21], rendering these knockin mice similar to
Figure 5.  BMP7 preferentially utilizes Alk2 in Bmpr2Δtd/+
PaSMCs.  (A) The ability of BMP4 or BMP7 (10 ng/ml for 1.5 h)
to induce Id1 and Smad6 gene expression, in Bmpr2Δtd/+
PaSMCs deficient in Alk2 or expressing Alk2 was examined by
qPCR. Id1 and Smad6 gene expression was normalized to
Gapdh and expressed as fold-change relative to Bmpr2Δtd/+;
Alk2flox/flox PaSMCs. *P < 0.01 compared to Bmpr2Δtd/+; Alk2flox/flox
PaSMCs treated with BMP7. (B) The ability of BMP4 or BMP7
(10 ng/ml for 1.5 h) to induce Id1 and Smad6 gene expression,
in Bmpr2Δtd/+ PaSMCs deficient in Alk3 or expressing Alk3 was
measured by qPCR. Id1 and Smad6 gene expression was
normalized to Gapdh and expressed as fold-change relative to
Bmpr2Δtd/+; Alk3flox/flox PaSMCs. *P < 0.01 compared to
Bmpr2Δtd/+; Alk3flox/flox PaSMC treated with BMP4.
doi: 10.1371/journal.pone.0076947.g005
haploinsufficient Bmpr2+/- mice. In contrast, BMPR2 R899X
protein was detected in the pulmonary vasculature of mice in
which a transgene specifying the mutant protein was inducibly
overexpressed in smooth muscle cells [22].
Mice with Bmpr2 mutations have been used to study how
human BMPR2 mutations might predispose carriers to PAH.
Bmpr2+/- mice express about 50% of Bmpr2+ mRNA levels and
manifest little [18] or no [23,24] pulmonary hypertension at
baseline; however, pulmonary hypertension induced by an
inflammatory stress [24] or an infusion of serotonin [23] is more
marked in Bmpr2+/- than in WT mice. Mice carrying one copy of
a mutant Bmpr2 allele lacking exon 2 (Bmpr2ΔE2) do not
manifest pulmonary hypertension at baseline but develop more
marked pulmonary hypertension after prolonged exposure to
hypoxia [25]. Although the main objective of our work was to
study the role of the tail domain of Bmpr2 using cells from
Bmpr2Δtd/+ mice, we did examine whether Bmpr2Δtd/+ mice
spontaneously develop pulmonary hypertension. At baseline,
RVSP does not differ in 6- to 8-month-old Bmpr2Δtd/+ and WT
mice. The absence of pulmonary hypertension at baseline in
mice carrying heterozygous Bmpr2 mutations (with mutant
Bmpr2 alleles expressed at levels similar to those of the WT
Figure 6.  Bmpr2‑TD attenuates Alk2‑mediated BMP7
signaling in PaSMCs.  Alk3‑deficient Bmpr2Δtd/+ PaSMCs were
transfected with specific siRNA to silence Bmpr2+
(siBmpr2‑ex12) or Bmpr2Δtd (siEgfp) transcripts. After 48 h, the
ability of BMP7 to induce Id1 and Smad6 gene expression was
measured by qPCR, normalized to Gapdh and expressed as
fold-change relative to Bmpr2Δtd/+; Alk3del/del PaSMCs treated
with siNC. *P < 0.01 compared to control cells (siNC) treated
with BMP7. Silencing efficiency was quantified by qPCR.
doi: 10.1371/journal.pone.0076947.g006
Bmpr2 Tail Domain Regulates BMP7 Signaling
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allele) is consistent with the observation that PAH occurs in
only one-fifth of the individuals harboring BMPR2 mutations,
suggesting that additional genetic or environmental factors
(second hit) are involved in the clinical manifestation of the
disease [14].
BMPs are involved in numerous processes during early
embryonic development including organogenesis and
morphogenesis [1]. We previously demonstrated that Bmpr2-/-
embryos are arrested during gastrulation [26]. In contrast, mice
homozygous for a hypomorphic Bmpr2 (Bmpr2ΔE2/ΔE2), which
appears to retain some BMP signaling capabilities, are able to
complete gastrulation, but die during midgestation due to
defects in the organogenesis of the cardiovascular and skeletal
systems [27]. In the present study, we observed that
homozygous Bmpr2Δtd/Δtd mice die in gastrulation even though
the Bmpr2‑ΔTD mutant retains the ability to activate Smads in
response to BMP ligands. These observations show that
embryogenesis not only requires Bmpr2 kinase activity, but
also the presence of the tail domain of Bmpr2.
To begin to understand how BMP signaling is modulated by
the absence of the tail domain of Bmpr2, we tested the
responsiveness of Bmpr2Δtd/+ PaSMCs to BMP4 and BMP7 and
found an unexpected BMP7‑specific gain of function. We
considered several possible mechanisms by which this gain of
function might occur. First, we considered the possibility that
the absence of the Bmpr2‑TD would alter the ability of the
receptor to traffic and localize to the cell membrane. In
Xenopus embryos, the neuroectodermal protein Jiraiya
interacts with a motif in the Bmpr2‑TD to inhibit bmpr2
trafficking to the cell membrane [28], suggesting that loss of the
tail domain may facilitate the trafficking of the receptor to the
cellular membrane. Moreover, it has been reported that
BMPR2 proteins with mutations in the tail domain can traffic to
the cellular membrane and can transduce BMP signaling
[29,30]. Similarly, we observed that Bmpr2‑ΔTD localized to the
cell membrane of PaSMCs. Taken together, these findings
demonstrate that the Bmpr2‑TD is not required for trafficking of
the receptor to the cell surface.
Previous reports have identified several proteins that can
interact with the tail domain of BMPR2 and regulate BMP
signaling. Tribbles homolog 3 (Trib3) interacts with the BMPR2-
TD and dissociates from the receptor upon BMP4 binding and
activation of the receptor complex [8]. Once unbound, Trib3
promotes the ubiquitination of SMURF1 (SMAD-specific E3
ubiquitin-protein ligase 1), thereby enhancing BMP signaling by
reducing the degradation of activated SMADs. Another protein
interacting with the BMPR2-TD, cGMP-dependent protein
kinase type I (PKG), phosphorylates the receptor leading to
enhanced BMP signaling [9]. Following BMP2 binding to the
receptor complex, PKG dissociates from the BMPR2-TD and
binds to activated SMADs and enhances their transcriptional
activity. However, loss of Trib3 or PKG binding to the tail
domain of BMPR2 is unlikely to explain the BMP7‑specific
increased responsiveness of cells expressing Bmpr2‑ΔTD.
We previously reported that Acvr2a transduced BMP4
signaling and was required for the enhanced BMP7 signaling
found in PaSMCs lacking Bmpr2 (Bmpr2del/del) [5]. We
considered the possibility that the BMP7‑specific gain of
function seen in PaSMCs carrying the Bmpr2Δtd allele was
exclusively transduced by Acvr2a. We observed, however, that
silencing of the Bmpr2Δtd allele in Bmpr2Δtd/+ PaSMCs markedly
reduced BMP7 signaling. Moreover, silencing Acvr2a
transcripts only modestly affected the ability of Bmpr2Δtd/+ or
Bmpr2Δtd/del PaSMCs to transduce BMP7 signaling. These
results demonstrate that the enhanced BMP7 signaling seen in
PaSMCs carrying the Bmpr2Δtd allele is predominantly
mediated by Bmpr2‑ΔTD rather than by Acvr2a. We previously
reported that knockdown of Acvr2a expression reduced BMP
signaling in Bmpr2del/del PaSMC but not in Bmpr2flox/flox cells. In
our current studies, we observed that BMP7 signaling was
greater in Bmpr2Δtd/del PaSMCs than in Bmpr2Δtd/flox PaSMCs.
Taken together, these observations suggest that the tail
domain of Bmpr2 can suppress BMP7 signaling transduced by
either Acvr2a or Bmpr2‑ΔTD.
Different BMPs have distinct affinities for each of the BMP
receptors. For example, BMP7 has a higher affinity for Alk2
than for other BMP type 1 receptors [19,20]. We therefore
tested the hypothesis that the enhanced BMP7 signaling seen
in cells expressing Bmpr2‑ΔTD is mediated by Alk2. In
Bmpr2Δtd/+ PaSMCs, deletion of Alk3 markedly reduced BMP4
signaling but not BMP7 signaling. In contrast, we observed that
deletion of Alk2 markedly impaired the ability of Bmpr2‑ΔTD to
transduce BMP7 signals. These results demonstrate that
Bmpr2‑ΔTD and Alk2 mediate BMP7 signaling in cells
harboring the Bmpr2Δtd allele. Taken together with our
observations in Bmpr2del/del PaSMC, these findings suggest that
the tail domain of Bmpr2 suppresses Alk2‑dependent BMP7
signaling by either Bmpr2‑ΔTD or Acvr2a and raise the
possibility that the the tail domain of Bmpr2 directly inhibits
Alk2 function. Unfortunately, currently available commercial
antibodies detect BMP type I receptors only when they are
overexpressed, hampering the detection of interactions of
endogenously expressed BMP receptors.
In conclusion, we report the generation of a mouse harboring
an NMD-resistant mutation in the sequences encoding for the
Bmpr2‑TD. Mice homozygous for the mutant allele died early in
embryogenesis, possibly because of a critical role for
Bmpr2‑TD in gastrulation. Heterozygous mice grow normally
and, as observed in genetically modified mice carrying other
mutant Bmpr2 alleles, they did not spontaneously develop
PAH. The BMP7‑specific gain of function observed in PaSMCs
from heterozygous Bmpr2Δtd/+ mice was mediated by the mutant
receptor and the BMP type 1 receptor, Alk2. Our data suggest
that BMP7 signaling is inhibited in WT PaSMCs by a restriction
exerted by the Bmpr2‑TD over Alk2. These data also raise the
possibility that some disease-causing BMPR2 mutations may
alter BMP signaling in a BMP ligand-specific manner.
Material and Methods
Generation of mice carrying mutant BMP receptors
The strategy to create the Bmpr2Δtd allele is shown in Figure
S1A. The Bmpr2Δtd-targeting vector carries sequences for Egfp
(in frame after exon 11), the SV40 polyadenylation signal
(SV40pA), and a phosphoglycerol kinase promoter-controlled
neomycin-resistance gene (PGK-neo) cassette after exon 11.
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Mouse embryonic stem (ES) cells were transfected with the
targeting vector, and Southern blot analysis identified an ES
cell clone with homologous recombination (Figure S1B). The
recombinant ES cells were injected into blastocysts and
germline transmission was achieved. Removal of the PGK-neo
cassette, flanked by loxP sequences, was achieved by mating
the heterozygous Bmpr2Δtd/+ mice with Ella-Cre transgenic
mice. Mice heterozygous for the Bmpr2Δtd allele were derived
from crossing chimeric mice with C57BL/6 female mice. PCR
analysis for genotyping purposes using DNA isolated from E7.5
embryos is shown in Figure S1C. Genotyping primers for the
mutant Bmpr2Δtd allele are 5’-
GTGCTACAGGCAGTGAGGTCACTC-3’ and 5’-
TAGGTCAGGGTGGTCACGAGGGTG-3’ (400-bp product).
Genotyping primers for Bmpr2+ allele are 5’-
GACTTCACACAGGCTGCAAATGGG-3’ and 5’-
CATACTGGGTTGTGGCAGCATGGG-3’ (300-bp product).
Bmpr2Δtd/+ mice were backcrossed more than 9 times onto a
C57BL/6 background. Bmpr2flox/flox mice [31] bred onto C57BL/6
background were bred to Bmpr2Δtd/+ mice to generate Bmpr2Δtd/
flox mice. Alk2flox/flox mice on a mixed C57BL/6; SV129
background [32] or Alk3flox/flox mice on a C57BL/6 background
[33] were bred to Bmpr2Δtd/+ mice to generate Bmpr2Δtd/+;
Alk2flox/flox, or Bmpr2Δtd/+; Alk3flox/flox mice, respectively.
All animal experiments were conducted under protocols
reviewed and approved by the Subcommittee on Research and
Animal Care of the Massachusetts General Hospital.
Hemodynamic measurements in Bmpr2Δtd/+ and WT
mice
Mice were anesthetized with ketamine (100 mg/kg) and
fentanyl (250 µg/kg) intraperitoneally, intubated, and
mechanically ventilated (10 µl/g, 100 breaths per minute; FiO2
= 1). Pancuronium (2 mg/kg) was administered
intraperitoneally, and a PE‑10 polyethylene catheter was
placed in the left carotid artery for continuous measurement of
heart rate and systemic arterial pressure. A 1.2F high-fidelity
pressure catheter (FTS‑1211B‑0018; Scisense, London, ON,
Canada) was advanced into the right ventricle via the jugular
vein to measure right ventricular systolic pressure (RVSP), as
an estimate of pulmonary arterial systolic pressure. All signals
were recorded and analyzed using a data acquisition system (A
D Instruments, Colorado Springs, CO). At the end of the study
mice were euthanized with an intraperitoneal injection of
pentobarbital (200 mg/kg).
PaSMC isolation and culture
Mice were euthanized with an intraperitoneal injection of
pentobarbital (200 mg/kg). Pulmonary arteries (PA) were
isolated and incubated individually in trypsin‑EDTA for 10 min
at 37°C. PAs were cut into ~1 mm3 pieces and enzymatically
digested using a solution of collagenase, papain, elastase, and
soybean trypsin inhibitor for 30 min at 37°C. After dissociation,
cells were washed twice in DMEM containing 20% fetal bovine
serum. After the final wash, cells were resuspended in DMEM
with 20% FBS and antibiotics (penicillin – streptomycin) and
were cultured at 37°C in 10% CO2. After the first passage, cells
were grown in DMEM containing 10% FBS. Cells were used for
experiments between passages 3 and 10.
Adenovirus infection
To disrupt Bmpr2, Alk2, or Alk3 genes in PaSMCs isolated
from mice harboring alleles carrying loxP sequences, cells
were infected with Ad-Cre or Ad-RFP, as a control, at a
multiplicity of infection of 150. After cells recovered from
infection, efficiency of recombination of the Bmpr2 allele
flanked by loxP sequences was determined by PCR and
immunoblot techniques, as reported previously [31]. Efficiency
of recombination of Alk2 or Alk3 alleles flanked by loxP
sequences was determined by qPCR using hydrolysis probes.
Small interfering RNA inhibition of BMP receptors
Silencer® Select siRNA (Applied Biosystems, Life
Technologies) specific for Bmpr2, Egfp, and Acvr2a or negative
control siRNA (30-50 nM) were transfected into PaSMCs using
Pepmute siRNA transfection reagent (SignaGen Laboratories),
as described by the manufacturer. After 48 hours, transfected
cells were starved in DMEM with 0.1% FBS for 12 to 16 hours
and then treated with BMP4 or BMP7.
Gene expression
Total RNA was extracted by guanidine isothiocyanate/phenol
method. cDNA was synthesized using M-MLV reverse
transcriptase and random primers (Promega). Id1, Smad6,
Bmpr2, Egfp, Acvr2a, Alk2, Alk3 and Gapdh transcript levels
were measured by qPCR in a Mastercycler ep realplex 2
(Eppendorf) using hydrolysis probes (TaqMan® Gene
Expression Assays, Applied Biosystems, Life Technologies)
and Probe Fast Master Mix (Kapa Biosystems). qPCR
reactions were prepared using the specific FAM-labeled
hydrolysis probes and the Gapdh VIC-labeled primer-limited
hydrolysis probe, as internal reference gene. Changes in
relative gene expression normalized to Gapdh mRNA levels
were determined using the relative CT method.
Immunoblot techniques
Confluent PaSMCs were incubated with DMEM with 0.1%
FBS for 12 to 16 hours and then treated for various times with
BMP4 or BMP7. Cells were lysed with RIPA buffer containing
proteinase and phosphatase inhibitor cocktails (Sigma).
Lysates were mixed with NuPAGE® LDS sample buffer
(Invitrogen, Life Technologies) containing 1mM DTT. Proteins
were separated by NuPAGE® Bis‑Tris gels (Invitrogen, Life
Technologies), transferred to polyvinylidene difluoride
membranes (Immobilon‑FL, Millipore), and blocked in TBS
containing 5% skim milk and 0.1% Tween 20. Membranes
were reacted with antibodies directed against phosphorylated
Smad1/5/8, Gapdh (Cell Signaling); as well as total Smad1/5/8
(Santa Cruz Biotechnology), the tail domain of Bmpr2 (BD
Transduction Laboratories), or GFP (Roche). After incubation
with HRP-conjugated IgG secondary antibodies (Epitomics and
Cell Signaling) and ECL Plus reagent (GE Healthcare Life
Sciences), chemifluorescence signals were detected with a
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Versadoc® Imaging Systems. Captured images were analyzed
with ImageJ software (NIH).
Immunofluorescence labeling
PaSMCs were transiently transfected with a plasmid carrying
the sequences of Bmpr2‑ΔTD. After 16 hours, cells were fixed
with 4% paraformaldehyde in PBS and permeabilized with
0.1% Triton X-100 in PBS. Immunohistochemical staining was
performed with a mouse anti-GFP antibody (Invitrogen, Life
Technologies), followed by incubation with fluorescein
isothiocyanate-labeled goat anti-mouse IgG. Subcellular
localization of Bmpr2‑ΔTD was determined by confocal laser
scanning microscopy.
Statistics
Differences between groups were determined using two-way
ANOVA for experiments using cultured PaSMCs. Figures show
results representative of three or more PaSMC isolates for
each genotype. For qPCR experiments, each experimental
condition was performed in quadruplicate. All data are
expressed as means ± standard deviation. The Student t‑test
was used to analyze mouse hemodynamic measurements (HR,
MAP, RVSP). A value of p < 0.05 indicated a significant
difference.
Supporting Information
Figure S1.  Bmpr2Δtd gene-targeting strategy. (A) Schematic
diagrams (from top to bottom) of the wild-type Bmpr2 gene, the
targeting vector, and the mutant Bmpr2Δtd allele after
homologous recombination. The entire tail domain of Bmpr2 is
encoded by exon 12 and 13. A genomic fragment containing
intron 11 and exon 12 was replaced by the sequence of Egfp
(in frame after exon 11) followed by SV40 polyA signal and a
PGK-neo cassette. (B) Southern blot analysis of DNA isolated
from ES clones. (C) PCR genotyping analysis of E7.5 embryos
generated by intercrosses of F1 heterozygotes.
(TIF)
Figure S2.  Hemodynamic measurements in Bmpr2+/+ and
Bmpr2Δtd/+ mice. Heart rate (HR), mean systemic arterial
pressure (MAP), and right ventricular systolic pressure (RVSP)
were measured in 6- to 8-month-old mice (littermates).
(TIF)
Figure S3.  Id1 gene expression in Bmpr2+/+ and Bmpr2Δtd/+
PaSMCs after 24 hours treatment with BMP4 or BMP7 (10
ng/ml; *p < 0.01 versus without BMP ligand).
(TIF)
Figure S4.  Immunoblotting of Bmpr2Δtd/flox and Bmpr2Δtd/del
PaSMCs with anti-Bmpr2‑TD to detect Bmpr2‑WT or anti-
GFP to detect Bmpr2‑ΔTD. Gapdh was used as loading
control.
(TIF)
Figure S5.  Concomitant loss of Alk2 and Alk3 prevents
BMP signaling in PaSMCs. (A) Bmpr2∆td/+; Alk2flox/flox; Alk3flox/flox
[+] or Bmpr2∆td/+; Alk2del/del; Alk3del/del [-] PaSMCs were
stimulated with BMP4 or BMP7 (10 ng/ml) for 30 min or 1 h.
Immunoblotting for pSmad1/5/8 and Smad1/5/8 show that
Bmpr2∆td/+ PaSMCs lacking the expression of Alk2 and Alk3
have lost the ability to phosphorylate BMP-responsive
Smad1/5/8. (B) Bmpr2+/+; Alk2flox/flox; Alk3flox/flox or Bmpr2+/+;
Alk2del/del; Alk3del/del PaSMCs were stimulated with BMP4 or
BMP7 (10 ng/ml) for 2 h, and the ability to induce Id1 and
Smad6 gene expression was measured by qPCR. Bmpr2+/+
PaSMCs lacking expression of Alk2 and Alk3 have lost the
ability to induce Id1 and Smad6 gene expression in response
to BMP ligands. (C) Bmpr2∆td/+; Alk2flox/flox; Alk3flox/flox or
Bmpr2∆td/+; Alk2del/del; Alk3del/del PaSMCs were stimulated with
BMP4 or BMP7 (10 ng/ml) for 2 h, and the ability to induce Id1
and Smad6 gene expression was measured by qPCR.
Bmpr2∆td/+ PaSMCs lacking expression of Alk2 and Alk3 have
lost the ability to induce Id1 and Smad6 gene expression in
response to BMP ligands.
(TIF)
Acknowledgements
The authors thank Yushi Mishina and Vesa Kaartinen for
providing Alk2+/flox and Alk3+/flox mice, respectively; Noriko
Kawai, Sharon M. Cawley and Andrea U. Steinbicker for
valuable technical advice; and Francesco Nordio and Andrea
Bellavia for statistical analyses.
Author Contributions
Conceived and designed the experiments: PAL HB KDB.
Performed the experiments: PAL HB AP TMM MD DMB RG
DBB. Analyzed the data: PAL HB AP TMM DMB DBB KDB.
Wrote the manuscript: PAL HB KDB.
References
1. Kishigami S, Mishina Y (2005) BMP signaling and early embryonic
patterning. Cytokine Growth Factor Rev 16: 265-278. doi:10.1016/
j.cytogfr.2005.04.002. PubMed: 15871922.
2. Miyazono K, Kamiya Y, Morikawa M (2010) Bone morphogenetic
protein receptors and signal transduction. J Biochem 147: 35-51. doi:
10.1093/jb/mvp148. PubMed: 19762341.
3. Schmierer B, Hill CS (2007) TGFbeta-SMAD signal transduction:
molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 8:
970-982. doi:10.1038/nrm2297. PubMed: 18000526.
4. Sieber C, Kopf J, Hiepen C, Knaus P (2009) Recent advances in BMP
receptor signaling. Cytokine Growth Factor Rev 20: 343-355. doi:
10.1016/j.cytogfr.2009.10.007. PubMed: 19897402.
5. Yu PB, Beppu H, Kawai N, Li E, Bloch KD (2005) Bone morphogenetic
protein (BMP) type II receptor deletion reveals BMP ligand-specific gain
Bmpr2 Tail Domain Regulates BMP7 Signaling
PLOS ONE | www.plosone.org 10 October 2013 | Volume 8 | Issue 10 | e76947
of signaling in pulmonary artery smooth muscle cells. J Biol Chem 280:
24443-24450. doi:10.1074/jbc.M502825200. PubMed: 15883158.
6. Kawabata M, Chytil A, Moses HL (1995) Cloning of a novel type II
serine/threonine kinase receptor through interaction with the type I
transforming growth factor-beta receptor. J Biol Chem 270: 5625-5630.
doi:10.1074/jbc.270.10.5625. PubMed: 7890683.
7. Beppu H, Minowa O, Miyazono K, Kawabata M (1997) cDNA cloning
and genomic organization of the mouse BMP type II receptor. Biochem
Biophys Res Commun 235: 499-504. doi:10.1006/bbrc.1997.6816.
PubMed: 9207184.
8. Chan MC, Nguyen PH, Davis BN, Ohoka N, Hayashi H et al. (2007) A
novel regulatory mechanism of the bone morphogenetic protein (BMP)
signaling pathway involving the carboxyl-terminal tail domain of BMP
type II receptor. Mol Cell Biol 27: 5776-5789. doi:10.1128/MCB.
00218-07. PubMed: 17576816.
9. Schwappacher R, Weiske J, Heining E, Ezerski V, Marom B et al.
(2009) Novel crosstalk to BMP signalling: cGMP-dependent kinase I
modulates BMP receptor and Smad activity. EMBO J 28: 1537-1550.
doi:10.1038/emboj.2009.103. PubMed: 19424179.
10. Morse JH, Jones AC, Barst RJ, Hodge SE, Wilhelmsen KC et al. (1997)
Mapping of familial primary pulmonary hypertension locus (PPH1) to
chromosome 2q31-q32. Circulation 95: 2603-2606. doi:
10.1161/01.CIR.95.12.2603. PubMed: 9193425.
11. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH et al. (1997)
Localization of the gene for familial primary pulmonary hypertension to
chromosome 2q31-32. Nat Genet 15: 277-280. doi:10.1038/
ng0397-277. PubMed: 9054941.
12. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW et al.
(2009) ACCF/AHA 2009 expert consensus document on pulmonary
hypertension a report of the American College of Cardiology
Foundation Task Force on Expert Consensus Documents and the
American Heart Association developed in collaboration with the
American College of Chest Physicians; American Thoracic Society,
Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol
53: 1573-1619. doi:10.1016/j.jacc.2009.01.004. PubMed: 19389575.
13. Fessel JP, Loyd JE, Austin ED (2011) The genetics of pulmonary
arterial hypertension in the post-BMPR2 era. Pulm Circ 1: 305-319. doi:
10.4103/2045-8932.87293. PubMed: 22140620.
14. Machado RD, Aldred MA, James V, Harrison RE, Patel B et al. (2006)
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial
hypertension. Hum Mutat 27: 121-132. doi:10.1002/humu.20285.
PubMed: 16429395.
15. Cogan JD, Pauciulo MW, Batchman AP, Prince MA, Robbins IM et al.
(2006) High frequency of BMPR2 exonic deletions/duplications in
familial pulmonary arterial hypertension. Am J Respir Crit Care Med
174: 590-598. doi:10.1164/rccm.200602-165OC. PubMed: 16728714.
16. Hamid R, Hedges LK, Austin E, Phillips JA 3rd, Loyd JE et al. (2010)
Transcripts from a novel BMPR2 termination mutation escape
nonsense mediated decay by downstream translation re-initiation:
implications for treating pulmonary hypertension. Clin Genet 77:
280-286. doi:10.1111/j.1399-0004.2009.01311.x. PubMed: 20095988.
17. Austin ED, Phillips JA, Cogan JD, Hamid R, Yu C et al. (2009)
Truncating and missense BMPR2 mutations differentially affect the
severity of heritable pulmonary arterial hypertension. Respir Res 10:
87. doi:10.1186/1465-9921-10-87. PubMed: 19785764.
18. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB et al. (2004) BMPR-II
heterozygous mice have mild pulmonary hypertension and an impaired
pulmonary vascular remodeling response to prolonged hypoxia. Am J
Physiol Lung Cell Mol Physiol 287: L1241-L1247. doi:10.1152/ajplung.
00239.2004. PubMed: 15286002.
19. Aoki H, Fujii M, Imamura T, Yagi K, Takehara K et al. (2001)
Synergistic effects of different bone morphogenetic protein type I
receptors on alkaline phosphatase induction. J Cell Sci 114:
1483-1489. PubMed: 11282024.
20. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M et al.
(1994) Identification of type I receptors for osteogenic protein-1 and
bone morphogenetic protein-4. J Biol Chem 269: 16985-16988.
PubMed: 8006002.
21. Nasim MT, Ogo T, Chowdhury HM, Zhao L, Chen CN et al. (2012)
BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses
through the activation of TGFbeta-TAK1-MAPK pathways in PAH. Hum
Mol Genet 21: 2548-2558. doi:10.1093/hmg/dds073. PubMed:
22388934.
22. West J, Harral J, Lane K, Deng Y, Ickes B et al. (2008) Mice expressing
BMPR2R899X transgene in smooth muscle develop pulmonary
vascular lesions. Am J Physiol Lung Cell Mol Physiol 295: L744-L755.
doi:10.1152/ajplung.90255.2008. PubMed: 18723761.
23. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X et al. (2006)
Serotonin increases susceptibility to pulmonary hypertension in
BMPR2-deficient mice. Circ Res 98: 818-827. doi:10.1161/01.RES.
0000215809.47923.fd. PubMed: 16497988.
24. Song Y, Jones JE, Beppu H, Keaney JF Jr., Loscalzo J et al. (2005)
Increased susceptibility to pulmonary hypertension in heterozygous
BMPR2-mutant mice. Circulation 112: 553-562. doi:10.1161/
CIRCULATIONAHA.104.492488. PubMed: 16027259.
25. Frank DB, Lowery J, Anderson L, Brink M, Reese J et al. (2008)
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2
mutant mice is associated with endothelial dysfunction in the pulmonary
vasculature. Am J Physiol Lung Cell Mol Physiol 294: L98-109.
PubMed: 18024717.
26. Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O et al. (2000)
BMP type II receptor is required for gastrulation and early development
of mouse embryos. Dev Biol 221: 249-258. doi:10.1006/dbio.
2000.9670. PubMed: 10772805.
27. Délot EC, Bahamonde ME, Zhao M, Lyons KM (2003) BMP signaling is
required for septation of the outflow tract of the mammalian heart.
Development 130: 209-220. doi:10.1242/dev.00181. PubMed:
12441304.
28. Aramaki T, Sasai N, Yakura R, Sasai Y (2010) Jiraiya attenuates BMP
signaling by interfering with type II BMP receptors in neuroectodermal
patterning. Dev Cell 19: 547-561. doi:10.1016/j.devcel.2010.09.001.
PubMed: 20951346.
29. Nishihara A, Watabe T, Imamura T, Miyazono K (2002) Functional
heterogeneity of bone morphogenetic protein receptor-II mutants found
in patients with primary pulmonary hypertension. Mol Cell Biol 13:
3055-3063. doi:10.1091/mbc.E02-02-0063. PubMed: 12221115.
30. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R et
al. (2002) Functional analysis of bone morphogenetic protein type II
receptor mutations underlying primary pulmonary hypertension. Hum
Mol Genet 11: 1517-1525. doi:10.1093/hmg/11.13.1517. PubMed:
12045205.
31. Beppu H, Lei H, Bloch KD, Li E (2005) Generation of a floxed allele of
the mouse BMP type II receptor gene. Genesis 41: 133-137. doi:
10.1002/gene.20099. PubMed: 15736264.
32. Dudas M, Sridurongrit S, Nagy A, Okazaki K, Kaartinen V (2004)
Craniofacial defects in mice lacking BMP type I receptor Alk2 in neural
crest cells. Mech Dev 121: 173-182. doi:10.1016/j.mod.2003.12.003.
PubMed: 15037318.
33. Mishina Y, Hanks MC, Miura S, Tallquist MD, Behringer RR (2002)
Generation of Bmpr/Alk3 conditional knockout mice. Genesis 32: 69-72.
doi:10.1002/gene.10038. PubMed: 11857780.
Bmpr2 Tail Domain Regulates BMP7 Signaling
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e76947
